» Articles » PMID: 2539062

Androgen Receptor in Hepatocellular Carcinoma As a Prognostic Factor After Hepatic Resection

Overview
Journal Ann Surg
Specialty General Surgery
Date 1989 Apr 1
PMID 2539062
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Androgen receptors (AR) in the cytosol of hepatocellular carcinoma (HCC) were assayed in 45 unselected patients in whom radical hepatic resection was performed. Thirty-one patients had detectable amounts of ARs in tumors, ranging from 2.3 to 82.6 fmol/mg protein with the dissociation constants (Kd) of 4.1 - 30.9 x 10(-10) M. The receptor was not found in the remaining 14 cases. AR negative HCCs were significantly more common among women and nonalcoholic patients. Otherwise, there were no significant difference in the clinicopathologic background between patients with AR positive HCCs and those with AR negative tumors. Three patients died of liver failure in the former group, whereas two died in the latter; one patient died of liver failure and the other died of pneumonia (results were not statistically significant). Excluding those five operative deaths, the recurrence rates were 67.9% in the group of patients with AR positive HCCs and 33.3% in the group of patients with AR negative tumors (0.1 less than p less than 0.05). The 5-year survival rate was significantly better (p less than 0.05) in patients with AR negative HCCs (62.2%) than in those with the positive tumors (17.3%). In light of the current results and previous experimental works by others, it is likely that testosterones enhance the growth and invasiveness of human HCC, which is mediated by AR in the tumor.

Citing Articles

Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression.

Dauki A, Blachly J, Kautto E, Ezzat S, Abdel-Rahman M, Coss C Cancer Res. 2019; 80(3):561-575.

PMID: 31685543 PMC: 7002251. DOI: 10.1158/0008-5472.CAN-19-1117.


Hepatocellular Carcinoma, Virilization, and Hilus Cell Hyperplasia in a Girl With Turner Syndrome.

Law J, Lee S, Sasatomi E, Bookhout C, Blatt J J Endocr Soc. 2018; 2(5):471-475.

PMID: 29732458 PMC: 5932469. DOI: 10.1210/js.2018-00017.


Overexpression of the androgen receptor in human hepatoma cells and its effect on fatty acid metabolism.

Kanda T, Jiang X, Nakamura M, Haga Y, Sasaki R, Wu S Oncol Lett. 2017; 13(6):4481-4486.

PMID: 28599448 PMC: 5453011. DOI: 10.3892/ol.2017.5973.


The androgen receptor as an emerging target in hepatocellular carcinoma.

Kanda T, Yokosuka O J Hepatocell Carcinoma. 2016; 2:91-9.

PMID: 27508198 PMC: 4918288. DOI: 10.2147/JHC.S48956.


Testosterone-receptor positive hepatocellular carcinoma in a 29-year old bodybuilder with a history of anabolic androgenic steroid abuse: a case report.

Solbach P, Potthoff A, Raatschen H, Soudah B, Lehmann U, Schneider A BMC Gastroenterol. 2015; 15:60.

PMID: 25986067 PMC: 4461943. DOI: 10.1186/s12876-015-0288-0.


References
1.
Wilkinson M, Iqbal M, Williams R . Characterisation of high affinity binding sites of androgens in primary hepatocellular carcinoma. Clin Chim Acta. 1985; 152(1-2):105-13. DOI: 10.1016/0009-8981(85)90181-0. View

2.
Hsu H, Wu T, Wu M, Sheu J, Lee C, Chen D . Tumor invasiveness and prognosis in resected hepatocellular carcinoma. Clinical and pathogenetic implications. Cancer. 1988; 61(10):2095-9. DOI: 10.1002/1097-0142(19880515)61:10<2095::aid-cncr2820611027>3.0.co;2-h. View

3.
Iqbal M, Wilkinson M, Johnson P, Williams R . Sex steroid receptor proteins in foetal, adult and malignant human liver tissue. Br J Cancer. 1983; 48(6):791-6. PMC: 2011561. DOI: 10.1038/bjc.1983.268. View

4.
Ostrowski J, Ingleton P, Underwood J, Parsons M . Increased hepatic androgen receptor expression in female rats during diethylnitrosamine liver carcinogenesis. A possible correlation with liver tumor development. Gastroenterology. 1988; 94(5 Pt 1):1193-200. DOI: 10.1016/0016-5085(88)90012-1. View

5.
MORRIS H, FIRMINGER H . Influence of sex and sex hormones on development of hepatomas and other hepatic lesions in strain AX C rats ingesting 2-diacetylaminofluorene. J Natl Cancer Inst. 1956; 16(4):927-49. View